New funding will power foundational primary cell data generation to advance AI-driven discovery through the company's full product launch. June 22, 2026 -- DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuin

AbbVie is making its biggest acquisition in years in a bid to expand its portfolio of autoimmune disease drugs, announcing on Monday plans to buy Apogee Therapeutics for nearly $11 billion. The pharmaceutical giant will pay $135.11 per share for Apogee, a roughly 49% premium to the biotechnology company’s closing price on Friday. The acquisition should close in the third quarter of 2026, pending approvals from shareholders and regulatory agencies. The Financial Times first reported news of a pe

Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation. In head-to-head non-human primate (NHP) studies, the average observed half-life of ASC35 was approximately six-fold longer than tirzepatide

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not show

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 June 23, 2026 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQU

ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received Orphan Designation from the European Commission, based on the recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of malignant mesothelioma, which

June 22, 2026 -- TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced that it has entered into an exclusive license agreement with Bionyra Pharma, a newly launched clinical-stage biopharmaceutical company, for TL-001, an anti-TL1A monoclonal antibody, and TL-003, a TL1A × IL-23p19 bispecific antibody. Under the terms of the agreement, Bionyra has

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) In connection with the transaction, Memento Medicines has closed a $93M Series A financing, co-led by Forbion, RA Capital Management and Avego BioScience Capital, to support the progress of MMT-205 through IND-enabling and clinical

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination ta

June 19, 2026 -- Zenyaku Kogyo Co., Ltd. (website in Japanese only) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Zenyaku, the marketing authorization holder, obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW), for an additional dosage and administration*1 of an anti-CD20 monoclonal antibody Rituxan® intravenous infusion 100 mg and 500 mg [generic name: rituximab (genetical recombination)] (hereafter “Rituxan”), which is co-promoted by bo